The use of health technology assessments (HTAs) to determine whether a healthcare technology should be paid for and at what price is well established in most countri...

Sridhar S et al. of JSS College of Pharmacy consider the haemovigilance system, which must include all appropriate stakeholders and coordinate between blood transfus...

With an ever-increasing amount of clinical trials reporting significant benefits in long-term overall survival of patients with specific cancers following mono-immun...

Diagnosing and treating rare and orphan diseases remains one of the life science sector’s great challenges. This is compounded by small patient populations, which ar...

Despite more people surviving cancer than ever before, a staggering 9.6 million people worldwide died from cancer in 20181, making the need for new drugs a global pr...

One of the most widely recognised limitations of traditional randomised clinical trials (RCTs) is that the observation period and treatment courses reflect only a fr...

The pharmaceutical sector’s fundamental purpose of advancing human health and its ambition to deliver drugs to market as rapidly, safely and cost-effectively as poss...